SMi proudly presents the return of the 5th annual ADC Summit to London in 2016!

With the FDA's recent approval of ADC's Adcetris® and Kadcyla ® , the industry has never been moving faster. With around 10 new ADC commercial launches over the coming decade, the report says the overall market will be worth USD 10 billion annually by 2025* and with most ADC research currently only in pre-clinical stages, we are yet to see the full market potential that ADCs are to contribute to the treatment of cancer. In an attempt to develop successors to Adcetris® and Kadcyla ® , the pharmaceutical industry is making every effort to produce the best next generation of ADCs by pioneering new approaches to eliminate cancer stem cells. As a result new innovations in conjugation methods and linker technology are bursting into the clinic at a rapid rate.

The introduction of second wave technology has seen a shift in industry from randomised cross linking technology to site directed technology, which has influenced a number of novel site specific conjugation techniques which have further influenced the next generation of ADCs. SMi's 5th annual ADC Summit brings you timely discussions to overcome ongoing challenges, including how to improve the therapeutic index of your ADC. Our 2-day event will provide a comprehensive analysis of the various approaches with the next generation ADCs. The conference will also focus on how to screen for optimal site of conjugation and offer some insight into how ADC can work in harmony with the field of oncology.


Join us today to:

• Hear the latest approaches to improve the therapeutic window of your ADC
• Discuss the latest innovations in site-specific conjugation technology
• Participate in insightful discussions on; novel payloads, folic acid drug conjugates, linker technology and many more!
• Engage in our interactive sessions and speed networking to solidify your learning experience amongst your peers



Chief Scientific Officer, Heads/Vice Presidents of Drug Discovery, CEO, Senior Scientist, Principal Scientists with responsibility in the following departments:-

• Biologics
• Antibody research
• Antibody conjugate development
• Antibody conjugate discovery
• Genomics Research
• Antibody Engineering
• Protein Sciences
• Protein Technologies
• Antibody and vaccine leads
• Monoclonal Antibody

Past attendees include:

Celgene, Spirogen, UCL, Sanofi, Novartis, GSK, PolyTherics, Merck, Pfizer, Imperial College, MedImmune, Genetech, Immunogen, Bicycle Therapeutics Limited, PhotoBiotics, Thomson Reuters, Glythera, UCB, Merrimack Pharmaceuticals, Agensys (an affiliate of Astellas), University of Oxford, GE Healthcare, Roche, Crescendo Biologics Ltd, Cristal Therapeutics, Regeneron Pharmaceuitcals Inc, Ablynx, Endocyte, Inc., Tagworks Pharmaceuticals, Genmab and many more!


Ablynx; ADC Biotechnology; Albany Molecular Research Inc; Antikor Biopharma Ltd.; Bicycle Therapeutics Limited; BioPharmaLogic Ltd.; Boult Wade Tennant; Clinical Network Services (UK) Ltd; Crescendo Biologics Ltd; Cristal Therapeutics; Endocyte, Inc.; GE Healthcare; Heraeus Precious Metals GmbH & Co. KG; ImmunoGen, Inc; ImmunoGen, Inc.; Imperial College London; Institut de Recherches Internationales Servier; King's College London; NanoTemper Technologies Ltd; NBE-Therapeutics AG; Novasep S A S; Philochem AG ; Queens University Belfast; Regeneron Pharmaceuitcals Inc; Roche Glycart AG; SafeBridge Europe, Limited; Selcia Ltd; Spirogen; Sygnature Discovery Limited; Tagworks Pharmaceuticals; University College London; University of Leeds;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Rakesh Dixit

Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

9:10 Advancement in antibody drug conjugates: A step closer to magic bullets in war against cancer

Rakesh Dixit

Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

• The 5 Rs of ADCs: the right target, the right linker, the right warhead, the right antibody, the right site of conjugation
• Recent developments with site-specific conjugation improving the therapeutic index of ADCs
• Exploring how reducing hydrophobicity of homogeneous ADCs can improve therapeutic index
• Discussing how the stability of the linker  can improve therapeutic index
• Discussing the on and off-target toxicity issues
• Clinical Development of ADCs

9:50 Warheads for targeted therapies of cancer: strategies for designing and efficient synthesis of DNA cross-linkers

Iontcho  Vlahov

Iontcho Vlahov, Vice President of Discovery Chemistry, Endocyte, Inc.

• Some DNA cross-linkers are too toxic to be used as antineoplastic agents; instead, they are excellent candidates for the design of ligand-drug conjugates for cancer targeting.
• New concept for design of DNA cross-linkers.
• Efficient total synthesis of cross-linker derivatives for conjugation.

10:30 Morning Coffee

11:00 Development of best-in-class, homogeneous ADCs for highly effective and safer cancer therapy

Roger Beerli

Roger Beerli, Chief Scientific Officer, NBE Therapeutics

• Sortase-mediated antibody conjugation (SMAC™): a robust and efficient means to attach toxic payloads to antibodies.
• Highly site-specific conjugation yields homogenous drug product with defined efficacy, PK properties and safety profile.
• Peptide-based linker structure circumvents IP issues and provides superior serum stability.
• In vivo data on lead ADCs generated using site-specific SMAC™-technology will be presented

11:40 Preclinical efficacy of a novel anti-C4.4a (LYPD3) antibody drug conjugate BAY 1129980 for the treatment of lung cancer

Joerg Willuda

Joerg Willuda, Senior Scientist, Bayer

• C4.4a (LYPD3) is a novel targeting antigen overexpressed in several cancer indications
• We will present the design of BAY 1129980 employing a novel auristatin
• We will discuss the in vitro and in vivo efficacy profile
• Phase 1 clinical studies are ongoing (NCT02134197)

12:20 Networking Lunch

13:30 Producing Better ADCs Using ThioBridge™ Conjugation

Matthew  Bird

Matthew Bird, Bioconjugation Team Leader, Abzena

• Disulfide re-bridging conjugation to reduce ADC heterogeneity
• ThioBridge™ linkers provide stable conjugation
• PK profiles of ThioBridge™ ADCs vs maleimide conjugation
• Development of more efficacious ADCs

14:10 Novel site-specific conjugation tools

Thomas Keating

Thomas Keating, Director, Biochemistry, Immunogen, Inc.

• N-terminal serine modification for antibody conjugation: SeriMabs
• Excellent in vitro activity achieved through site-specific conjugation
• Site-specific conjugates are stable and efficacious in vivo

14:50 Afternoon Tea

15:20 Expanding the scope of ADC targets through novel conjugation technologies

Sasha Koniev

Sasha Koniev, CEO & Co Founder, Syndivia

• APN linkers with increased serum stability
• New generation of DM1- and MMAE-based payloads
• Expanding the scope of ADC targets by fine-tuning the drug release mechanism

16:00 Platform Technologies for Homogeneous and Versatile Protein Modification

Vijay Chudasama

Vijay Chudasama, Lecturer (Organic Chemistry and Chemical Biology), University College London

• Functional disulfide re-bridging
• Controlled dual “click” functionalisation
• Site-selective antibody conjugation
• Photodynamic therapy
• Reversible and irreversible cysteine modification

16:40 Chairman’s Closing Remarks and Close of Day One

Rakesh Dixit

Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mahendra  Deonarain

Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.

9:10 ADCETRIS® (brentuximab vedotin) developed to treat Hodgkin

Ashish Gautam

Ashish Gautam, Global Medical Lead - ADCETRIS, Takeda Pharmaceuticals

• Development of ADCETRIS® - Takeda and Seattle Genetics
• Exploring the mechanism pathway of ADCETRIS®
• Data published to date from ADCETRIS® registration studies
• Ongoing ADCETRIS® clinical development

9:50 Predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies

Ben-Fillippo  Krippendorff

Ben-Fillippo Krippendorff, Principal Scientist , Roche Pharmaceuticals

• Estimating the tissue distribution of antibodies and antibody fragments based on plasma pharmacokinetics
• Estimation of ADC distribution and tissue specific clearances that influence the therapeutic window
• Optimise biotherapeutic modalities with optimal biodistribution properties to target (and avoid) specific tissues

10:30 Morning Coffee

11:00 Impact of drug loading on ADC target binding and cytotoxicity

Debra Meyer

Debra Meyer, Senior Principal Scientist, Pfizer

• Case studies will be presented demonstrating the impact of different levels of drug loading on ADC target binding and cytotoxcity

11:40 Developments in high potency API manufacturing

Richard Denk

Richard Denk, Containment Sales, SKAN AG

  • What does containment mean for very low OEL’s
  • How to design the containment for the
    API production as well as for the aseptic
  • Case study on a low OEL aseptic processing
  • 12:30 Networking Lunch

    13:30 Engineering and development of novel immunotargeted nanotherapeutics

    Daryl Drummond

    Daryl Drummond, Vice President, Discovery , Merrimack Pharmaceuticals Inc

    • Engineering considerations for a novel antibody directed nanotherapeutic
    • Target expression and demonstration of targeting
    • Preclinical demonstration of activity and altered tox profile
    • Diagnostic development and clinical trial design for upcoming Phase I

    14:10 The design, synthesis and scale-up of an ADC tubulysin payload

    Jeremy Parker

    Jeremy Parker, Principal Scientist, AstraZeneca

    • Development of novel ADC payloads based on Tubulysins
    • Identification and development of synthetic routes
    • Scale up of chemistry to deliver material for toxicology and clinical studies

    14:50 Afternoon Tea

    15:20 Challenges and lessons learnt in ADC CMC development and outsourcing

    Jens Lohrmann

    Jens Lohrmann, Senior Global Program Manager, Translational Clinical Oncology, Novartis

    • Buy vs. make: considerations and critical success factors
    • Scale-up and site transfer of a conjugation process with impact on key product quality attributes: case studies
    • Analytical transfers: considerations and lessons learned from a challenging assay transfers

    16:00 FDCs (Fragment Drug Conjugates): A unique drug class or just smaller ADCs?

    Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.

    • Using optimised single chain Fvs to obtain high DAR
    • Impact of drug/linker structure on FDC properties
    • Dosing, PK and penetration issues

    16:40 Chairman’s Closing Remarks and Close of Day Two

    Mahendra  Deonarain

    Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.


    Sponsors and Exhibitors

    Official Media Partner



    ADC Payloads: Availability and Mechanisms of Action

    ADC Payloads: Availability and Mechanisms of Action

    Holiday Inn Kensington Forum
    25th May 2016
    London, United Kingdom

    Preliminary list of attendees - 2016


    Interview with Mahendra Deonarain


    Sponsors and Exhibitors


    Sponsors and Exhibitors

    Abzena offers a suite of complementary services and technologies. Its range of technologies include immunogenicity assessment, antibody drug conjugation, protein engineering, PEGylation, cell line development , GMP manufacturing and a range of bespoke assays to enables the development of better biopharmaceuticals which will have a greater chance of reaching the market.


    Sponsors and Exhibitors

    Heraeus’ Business line Pharmaceuticals is the specialist in cytotoxic agents for nearly 30 years. We hold globally a leading position in supply of precious metals based API as well as generic cytotoxic agents Heraeus comprehensive custom services is focused on the synthesis of highly potent compounds (precious metal compounds and small molecules) under high containment conditions and full GMP. In the field of Antibody-Drug-Conjugates our strengths is in payloads. For more details please visit our website www.heraeus-chemicals.com

    Media Partners

    BioChem Adda

    Official Media Partner

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

    ADC Review

    Official Media Partner

    ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international publication combining professional social media with an online-only, hybrid open-access, peer reviewed journal. The Journal aims to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. Key information includes peer-reviewed articles, news features, discussions, blogs, and a knowledge center offering the latest and most relevant information about Antibody Drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.

    The Pharma Letter

    Official Media Partner

    The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.

    WCA Pharma

    Official Media Partner

    The Members within WCA Pharma all have dedicated personnel fully conversant in the GDP guidelines required for the special handling of Pharmaceutical products. All have the attention to detail required that has seen them become established and recognized by the leading Pharma Industries throughout the world. From Clinical trials, Biotech, Plasma, Laboratory, Health Care, Chilled, Frozen, Controlled Ambient, Packaging, Air, Ocean and Land, you have all Pharmaceutical clusters contained within one exclusive network. Our members are able to pass on their knowledge to clients and use their skills, trust and experience in ensuring all products arrive on time and in the perfect condition. Making sure products are shipped via the correct method, temperature, atmosphere and under controlled conditions ensures these valuable shipments have the care and attention whilst being handled that they deserve.


    Official Media Partner

    ecancer is the leading oncology channel committed to improving cancer communication and education with the goal of optimising patient care and outcomes. By using the latest technologies ecancer works closely with leading figures in oncology to inform and educate the global cancer community.

    Media Partners

    British Pharmacological Society


    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.



    Pharmatching.com is an efficient, targeted and easy-to-use-“Web2.0”-tool for finding the right partners in the pharmaceutical industry worldwide. It saves time and costs in all (out)sourcing and business development processes, as it fascilitates and accelerates the searching process for appropriate business partners significantly. Pharmatching.com is particularly advantageous for projects where a special service is (immediately) required or to offer capacities which are currently available. It is useful for services in all categories and stages of drug development including contract manufacturing, contract research, laboratory investigations, contractual testing, non-clinical and clinical research, active pharmaceutical ingredients, consulting, marketing, registration, in- and outlicensing etc.



    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    Antibodies Online


    antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.



    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.





    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!

    International Journal of Biomedical Engineering and Technology


    IJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).

    Bentham Science


    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here

    Swiss Biotech Association


    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    Select Science


    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

    Int. J. of Immunological Studies


    IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.

    International Journal of Environment and Health


    IJEnvH is a fully-refereed scientific journal that provides an international forum for the exchange of information and the advancement of knowledge in the multidisciplinary field of environment and health. The aim of IJEnvH is to stimulate the discussion and communication among scientists, researchers and experts with different background and expertise, involved, at different levels, with the study of environment and health problems.

    Drug Discovery World


    For over a decade DDW has continued to be the ‘must read’ journal within the DD&D Arena. DDW is recognised for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised platform for Industry Gurus to debate some of the more challenging technological and business issues facing the the life science industry. DDW adheres to the maxim..... ‘Turning Science into Business’ DDW examines the advances in new technologies and the associated implications within the context of developing new and efficacious therapeutics. DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level, allowing both camps to profit from the uncomplicated style of editorial but at the same time challenges our readers to look at new ways to overcome discovery bottlenecks, embrace nascent technologies and build next generation technology platforms.



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

    Drug Target Review


    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.

    Drug Discovery Today


    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

    International Journal of Computational Biology and Drug Design


    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.



    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

    Pharmaceutical Business Review


    The Business Review websites are your number one stop for all the latest news, comment and industry information. Each Business Review website offers content that is produced by a dedicated team of journalists and global industry experts. It enables you to keep ahead of the latest news relating to your industry. Read independent analysis of the latest issues and developments that affects your business. Target new business leads and Identify potential channels, and benchmark your organisation against others in the industry.



    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.



    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.



    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.

    Pharmaceutical Technology


    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.



    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

    International Journal of Healthcare Technology and Management


    IJHTM is a series emerging from the International Journal of Technology Management. It provides an international forum and refereed authoritative sources of information in the fields of the economics and management of technology in healthcare.



    The complete and transparent marketplace for your research antibodies, kits, proteins and small molecules. The sophisticated search engine, with more than 800.000 products, transparency in suppliers, easy comparison, the one stop shop for your research antibodies in combination with interesting news and events plus a CMO exchange makes us a full service partner for you.

    Thomson Reuters


    Thomson Reuters is the leading source of intelligent information for professionals around the world. We provide essential information to keep you in touch with the rapidly-changing pharmaceutical and chemical markets, expert services to help you make informed, early decisions, and intuitive technology to manage and support your discovery and development activities. Our products give you the intelligence, tools and expertise to help you optimize your IP portfolio, monitor industry developments, identify licensing and partnering opportunities, deliver successful regulatory submissions, and support your scientific messaging, marketing, product positioning, and awareness campaigns.

    Contract Biotechnology


    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.



    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.

    Int. J. of Biotechnology


    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.

    WCA Time Critical




    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out